Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Blackrock Neurotech’s MoveAgain Brain-Computer Interface System Receives Breakthrough Device Designation from the FDA

Blackrock Neurotech, the leader in brain-computer interface technology, today announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its groundbreaking MoveAgain Brain Computer Interface (BCI) System.

The first-of-its-kind system is expected to provide immobile patients the ability to control a mouse cursor, keyboard, mobile device/tablet, wheelchair or prosthetic device simply by thinking.
The FDA Breakthrough Device designation aims to expedite the review of innovative technologies that can improve the lives of people with irreversibly debilitating diseases or conditions. Approximately 5.35 million people in the United States live with some form of paralysis as a result of central nervous system disorders, autoimmune diseases and spinal cord injuries (SCIs). Many of these patients are completely dependent on permanent support from a caretaker, and their ability to communicate or control their external environment is severely limited.
Blackrock’s portable MoveAgain BCI could offer these patients new possibilities for improved mobility and independence – such as returning to work, participating in leisure activities, and communicating more effectively and quickly. The goal of the device is to achieve long-term improvement in movement and independence, reduce patient reliance on caregivers and help them better engage with society and the world.
“We look forward to working closely with the FDA to prioritize development of the MoveAgain Brain-Computer Interface System, which will bring us closer to our goal of commercialization in 2022.  Patients with tetraplegia are eager to get access, and we are committed to advancing their ability to increase their independence with our BCI technology,” said Marcus Gerhardt, co-founder and CEO of Blackrock Neurotech.
The MoveAgain BCI system is built upon 25 years of groundbreaking clinical research in humans conducted by a number of leading institutions. The system consists of an array implanted in the brain, which decodes intended movement from neuronal activity. Those signals are then transmitted wirelessly to an external device, such as a cursor or wheelchair, providing people with control of their external environment.
“We are very grateful that commercialization of these life-changing products is now possible.,” said Florian Solzbacher, Chairman and President of Blackrock Neurotech. “We are confident we have sufficient safety and efficacy data to support the first applications, and very large-scale integration technologies have allowed further miniaturization, which will make a robust wireless version possible. We look forward to submitting plans to make these products widely available in 2022.
To qualify for the Breakthrough Device designation, a device must represent a novel application of an existing technology, and show that it has the potential to provide for more effective treatment of irreversibly debilitating diseases or conditions. The goal of the program is to provide patients and clinicians more timely access to these breakthrough devices by accelerating their development, assessment, and review, while preserving statutory standards for pre-market approval.
“We are seeing the beginning of a revolution in the diagnosis and treatment of neurological disorders and disabilities,” said Solzbacher. “Ten years from now, neural implants could be as common as cardiac pacemakers are today — offering patients a whole new world of options that restore their independence.”
1 Early research began at the University of Utah and Braingate; see: https://www.nature.com/articles/nature04970
2 University of Pittsburgh, Brown University, Massachusetts General Hospital, John Hopkins University, Ohio State University, Battelle Memorial Institute,  Case Western Reserve University, Wyss Center, University of Geneva, TU Munich, Thomas Jefferson University, California Institute of Technology, Rancho Los Amigos National Rehabilitation Center, University of Southern California, University of California Los Angeles, Casa Colina Centers for Rehabilitation, Stanford University, Zhejiang University, The University of Chicago, Providence VA Medical Center, Louis Stokes VA Medical Center,  Fundación Tecnalia Research & Innovation: San Sebastian, University Miguel Hernandez, Elche, Spain,  and others.
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy